Literature DB >> 11084685

The genodermatoses: candidate diseases for gene therapy.

J Uitto1, L Pulkkinen.   

Abstract

Tremendous progress has been made in understanding the genetic basis of different forms of genodermatoses, a group of heritable diseases displaying a spectrum of phenotypic manifestations and clinical severity. The information about the underlying mutations in the candidate gene/protein systems has provided the basis for initial development of cutaneous gene therapy, and these heritable conditions appear to serve as appropriate candidate diseases for such efforts. Because of its accessibility and the fact that resident skin cells, such as epidermal keratinocytes and dermal fibroblasts, can be readily propagated in culture, skin serves as an appropriate target tissue for gene therapy. Various strategic considerations, including the use of in vivo or ex vivo approaches, gene replacement versus gene repair, utilization of different delivery systems, etc., require careful prioritization depending on the type of mutations and their pathogenetic consequences at the mRNA and protein levels.

Mesh:

Substances:

Year:  2000        PMID: 11084685     DOI: 10.1089/104303400750035807

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  9 in total

1.  Topical colchicine selection of keratinocytes transduced with the multidrug resistance gene (MDR1) can sustain and enhance transgene expression in vivo.

Authors:  W Pfutzner; A Terunuma; C L Tock; E K Snead; T M Kolodka; M M Gottesman; L Taichman; J C Vogel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

2.  Silencing of reporter gene expression in skin using siRNAs and expression of plasmid DNA delivered by a soluble protrusion array device (PAD).

Authors:  Emilio Gonzalez-Gonzalez; Tycho J Speaker; Robyn P Hickerson; Ryan Spitler; Manuel A Flores; Devin Leake; Christopher H Contag; Roger L Kaspar
Journal:  Mol Ther       Date:  2010-06-22       Impact factor: 11.454

3.  Efficient in vivo targeting of epidermal stem cells by early gestational intraamniotic injection of lentiviral vector driven by the keratin 5 promoter.

Authors:  Masayuki Endo; Philip W Zoltick; William H Peranteau; Antoneta Radu; Nidal Muvarak; Mayumi Ito; Zaixin Yang; George Cotsarelis; Alan W Flake
Journal:  Mol Ther       Date:  2007-10-09       Impact factor: 11.454

4.  Host immune responses in ex vivo approaches to cutaneous gene therapy targeted to keratinocytes.

Authors:  Z Lu; S Ghazizadeh
Journal:  Exp Dermatol       Date:  2005-10       Impact factor: 3.960

5.  Immune-mediated loss of transgene expression in skin: implications for cutaneous gene therapy.

Authors:  Soosan Ghazizadeh; Richard S Kalish; Lorne B Taichman
Journal:  Mol Ther       Date:  2003-03       Impact factor: 11.454

6.  Topical delivery of siRNA into skin using SPACE-peptide carriers.

Authors:  Ming Chen; Michael Zakrewsky; Vivek Gupta; Aaron C Anselmo; Deborah H Slee; John A Muraski; Samir Mitragotri
Journal:  J Control Release       Date:  2014-01-13       Impact factor: 9.776

Review 7.  Progress in heritable skin diseases: translational implications of mutation analysis and prospects of molecular therapies*.

Authors:  Jouni Uitto
Journal:  Acta Derm Venereol       Date:  2009       Impact factor: 4.437

8.  Preimplantation Genetic Diagnosis for DEB by Detecting a Novel Family-Specific COL7A1 Mutation in Vietnam.

Authors:  Sang Trieutien; Tam Vu Van; My Tran Ngoc Thao; Son Trinh The; Khoa Tran Van; Tung Nguyen Thanh; Tuan Tran Van; Hanh Nguyen Thi
Journal:  Appl Clin Genet       Date:  2021-12-09

9.  Transgene-specific host responses in cutaneous gene therapy: the role of cells expressing the transgene.

Authors:  Z Zhang; C Kuscu; S Ghazizadeh
Journal:  Gene Ther       Date:  2009-05-14       Impact factor: 5.250

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.